472 related articles for article (PubMed ID: 25939897)
1. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
Gao Y; Guo X; Han P; Li Q; Yang G; Qu S; Yue L; Wang CN; Skljarevski V; Dueñas H; Raskin J; Gu L
Int J Clin Pract; 2015 Sep; 69(9):957-66. PubMed ID: 25939897
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial.
Upadhyaya HP; Arnold LM; Alaka K; Qiao M; Williams D; Mehta R
Pediatr Rheumatol Online J; 2019 May; 17(1):27. PubMed ID: 31138224
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.
Pritchett YL; McCarberg BH; Watkin JG; Robinson MJ
Pain Med; 2007; 8(5):397-409. PubMed ID: 17661853
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study.
Wang G; Bi L; Li X; Li Z; Zhao D; Chen J; He D; Wang CN; Dueñas H; Skljarevski V; Yue L
Osteoarthritis Cartilage; 2017 Jun; 25(6):832-838. PubMed ID: 28043937
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients.
Murakami M; Osada K; Mizuno H; Ochiai T; Alev L; Nishioka K
Arthritis Res Ther; 2015 Aug; 17(1):224. PubMed ID: 26296539
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
Raskin J; Pritchett YL; Wang F; D'Souza DN; Waninger AL; Iyengar S; Wernicke JF
Pain Med; 2005; 6(5):346-56. PubMed ID: 16266355
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc Analysis.
Tanenberg RJ; Clemow DB; Giaconia JM; Risser RC
Pain Pract; 2014 Sep; 14(7):640-8. PubMed ID: 24152185
[TBL] [Abstract][Full Text] [Related]
9. Does pain cause the perception of fatigue in patients with chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.
Fishbain DA; Hall JA; Risser RC; Gonzales JS
Pain Pract; 2009; 9(5):354-62. PubMed ID: 19500272
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome.
Arnold LM; Blom TJ; Welge JA; Mariutto E; Heller A
Psychosomatics; 2015; 56(3):242-53. PubMed ID: 25660434
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China.
Gao Y; Ning G; Jia WP; Zhou ZG; Xu ZR; Liu ZM; Liu C; Ma JH; Li Q; Cheng LL; Wen CY; Zhang SY; Zhang Q; Desaiah D; Skljarevski V
Chin Med J (Engl); 2010 Nov; 123(22):3184-92. PubMed ID: 21163113
[TBL] [Abstract][Full Text] [Related]
12. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
Wernicke JF; Wang F; Pritchett YL; Smith TR; Raskin J; D'Souza DN; Iyengar S; Chappell AS
Pain Med; 2007 Sep; 8(6):503-13. PubMed ID: 17716324
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
[TBL] [Abstract][Full Text] [Related]
14. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?
Marchettini P; Wilhelm S; Petto H; Tesfaye S; Tölle T; Bouhassira D; Freynhagen R; Cruccu G; Lledó A; Choy E; Kosek E; Micó JA; Späth M; Skljarevski V; Lenox-Smith A; Perrot S
Eur J Pain; 2016 Mar; 20(3):472-82. PubMed ID: 26311228
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
16. Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
Matsuoka H; Ishiki H; Iwase S; Koyama A; Kawaguchi T; Kizawa Y; Morita T; Matsuda Y; Miyaji T; Ariyoshi K; Yamaguchi T
BMJ Open; 2017 Aug; 7(8):e017280. PubMed ID: 28851798
[TBL] [Abstract][Full Text] [Related]
17. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.
Tesfaye S; Sloan G; Petrie J; White D; Bradburn M; Julious S; Rajbhandari S; Sharma S; Rayman G; Gouni R; Alam U; Cooper C; Loban A; Sutherland K; Glover R; Waterhouse S; Turton E; Horspool M; Gandhi R; Maguire D; Jude EB; Ahmed SH; Vas P; Hariman C; McDougall C; Devers M; Tsatlidis V; Johnson M; Rice ASC; Bouhassira D; Bennett DL; Selvarajah D;
Lancet; 2022 Aug; 400(10353):680-690. PubMed ID: 36007534
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies.
Kajdasz DK; Iyengar S; Desaiah D; Backonja MM; Farrar JT; Fishbain DA; Jensen TS; Rowbotham MC; Sang CN; Ziegler D; McQuay HJ
Clin Ther; 2007; 29 Suppl():2536-46. PubMed ID: 18164920
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.
Wu EQ; Birnbaum HG; Mareva MN; Le TK; Robinson RL; Rosen A; Gelwicks S
J Pain; 2006 Jun; 7(6):399-407. PubMed ID: 16750796
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine vs. placebo in patients with painful diabetic neuropathy.
Goldstein DJ; Lu Y; Detke MJ; Lee TC; Iyengar S
Pain; 2005 Jul; 116(1-2):109-18. PubMed ID: 15927394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
